CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 456 target
Drug / intervention
Full course of PD-1blockades +4 moredrug
Likely dose
Full course of PD-1blockades 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07328841
NCT07328841Phase 3RecruitingOn TrackUpdated 5mo ago
CompareCT.gov

Reduced-Dose Versus Conventional-Dose Intensity-Modulated Radiation Therapy in Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy: A Multicenter, Phase III Clinical Trial

Ming-Yuan Chen·interventional·Posted Jan 9, 2026·Updated Jan 9, 2026

In Brief

A Phase 3 clinical trial evaluating Full course of PD-1blockades, Cisplatin-based induction chemotherapy, and 3 other interventions for Nasopharyngeal Carcinoma (NPC). Currently recruiting, targeting 456 participants across 12 sites.

Detailed Summary

To explore the efficacy and safety of reduced-dose radiotherapy combined with concurrent chemotherapy and immunotherapy in stage Ⅳa (AJCC 8th,) locally advanced nasopharyngeal carcinoma patients who are sensitive to induction chemoimmunotherapy (assessed as complete response \[CR\]/partial response \[PR\] by imaging, with EBV DNA copy number reduced to zero or below the lower limit of detection), so as to provide a new treatment option for these patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma (NPC)
CountriesChina
Collaborators--

Timeline

Phase 3Recruiting
2026202720282029203020312032
First PostedJan 9, 2026
Enrollment StartNov 18, 2025
Primary CompletionJun 30, 2030
Study CompletionJun 30, 2032
TodayJul 1, 2026
Enrollment to primary: 4.6 yearsPosted 6 months agoPrimary completion in 4.0 years

Interventions

Full course of PD-1blockadesdrug

Toripalimab 240 mg, once every 3 weeks (Q3W), intravenous infusion (iv). A total of 12 courses of treatment will be administered, including 3 courses during the induction chemotherapy phase, 3 courses during the radiotherapy phase, and 6 courses during the post-radiotherapy maintenance phase. Administration will start on Day 1 of induction chemotherapy and continue after the end of radiotherapy until the occurrence of intolerable toxicities, disease progression, withdrawal of consent, determination by the investigator that the patient needs to withdraw from treatment, or the completion of 12 courses, whichever comes first.

Cisplatin-based induction chemotherapydrug

Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.

Standard-dose radiotherapyradiation

GTVnx/nd:69.96Gy/33Fr/2.12Gy CTV1: 59.4Gy/33Fr/1.8Gy CTV2: 54.12Gy/33Fr/1.64Gy

Reduced-dose radiotherapyradiation

GTVnx/nd:63.6Gy/30Fr/2.12Gy CTV1: 54Gy/30Fr/1.8Gy CTV2: 49.2Gy/30Fr/1.64Gy

Concurrent Chemotherapydrug

Cisplatin 100mg/m2 every 3 weeks for 2 cycles